Therapy News and Research

RSS

Research marks new direction to treat Pneumocystis, inflammatory diseases

A drug to treat inflammation plays a surprising role reducing the level of infection caused by an opportunistic bug that is deadly for AIDS and cancer patients and others with weakened immune systems.

20 Aug 2010

Muscular Dystrophy Association awards $14.1M in new grants

The Muscular Dystrophy Association, which has invested almost $39 million in 2010 in worldwide research seeking treatments and cures for muscle diseases, today announced that it has awarded $14.1 million in new grants.

20 Aug 2010

FDA grants priority review designation of BENLYSTA for systemic lupus erythematosus treatment

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has granted a priority review designation to BENLYSTA (belimumab) as a potential treatment for systemic lupus erythematosus.

20 Aug 2010

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today provided an update on the clinical development program for its proprietary product for non-muscle-invasive bladder cancer - Urocidin.

20 Aug 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

Metagenics announces acquisition of Catalina Lifesciences

Metagenics, Inc., a San Clemente, California-based life sciences company, today announced its acquisition of Catalina Lifesciences, Inc., the Irvine, California-based maker of Bariatric Advantage.

20 Aug 2010

PharmaVentures announces global expansion of PharmaDeals Agreements

PharmaVentures, the company behind the PharmaDeals(R) range of business information, announced today the expansion of its PharmaDeals Agreements coverage that includes exclusive interviews with deal makers around the world. The announcement follows major enhancement of its dedicated, market leading platform delivering deal data and information to the pharmaceutical and biotechnology sector.

19 Aug 2010

Innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells

Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy describes an innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells. This approach if successful could lead into an anti-HIV therapy that will eradicate the virus.

19 Aug 2010

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.

19 Aug 2010

Celera Corporation releases review article on KIF6 gene variant for CHD

Celera Corporation today announced the publication of a review article on the KIF6 gene variant as a predictor of risk of coronary heart disease (CHD) and reduction of CHD events from statin therapy.

19 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

EHSI signs option with Regenevita for 'Neo Natal Progenitor Cell Expansion Technology'

Emerging Healthcare Solutions, Inc. announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion.

19 Aug 2010

Maternal stress contribute to an elevated risk for depression in offspring: Research

For more than a century, clinical investigators have focused on early life as a source of adult psychopathology. Although the hypothesized mechanisms have evolved, a central notion remains: early life is a period of unique sensitivity during which experience confers enduring effects.

19 Aug 2010

MD Anderson Cancer Center receives $20 million to advance research on targeted therapies

Dallas businessman and philanthropist H. Ross Perot has donated $20 million to The University of Texas MD Anderson Cancer Center for research to advance and design novel targeted therapies.

19 Aug 2010

Scientists reveal lab approach method to treat neuroblastoma in children

A study led by scientists at The Hospital for Sick Children (SickKids) reveals a new method of identifying drugs to treat children suffering from fatal cancers for which an effective treatment has not been found. Rather than developing a new drug from scratch, which is a complicated and time-consuming process, they tried a different approach: in the lab, they tested existing drugs on cancer stem cells from young patients with neuroblastoma, one of the common cancers of infants and children.

19 Aug 2010

Siemens Healthcare to distribute Calypso GPS System in Europe

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced that it has entered into a non-exclusive product distribution agreement with Siemens Healthcare for the sale of its Calypso® System in Europe. Under terms of the agreement, Siemens retains non-exclusive rights to sell Calypso's real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for a period of three years.

19 Aug 2010

FDA accepts to review Bristol-Myers Squibb's ipilimumab for melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. The company also announced today that the application has been granted a priority review designation by the FDA.

19 Aug 2010

Behavioral Innovations includes In-home Autism Treatment programs in ABA services at San Antonio

SANBehavioral Innovations, the premier provider of Applied Behavior Analysis (ABA) services for families of children with Autism and other developmental disorders, announces the expansion of its San Antonio services to include In-home Autism Treatment programs and consultation services for schools and professionals.

19 Aug 2010

Rush University Medical Center tests new drug therapy for West Nile fever

Neurological and infectious disease experts at Rush University Medical Center are testing a new drug therapy for the treatment of individuals with West Nile fever or suspected central nervous system infection due to the West Nile virus. Rush is the only site in the Midwest enrolling patients into the $50 million dollar, NIH-funded, Phase II clinical trial called PARADIGM.

18 Aug 2010

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications.

18 Aug 2010

Therapy News and Research

Research marks new direction to treat Pneumocystis, inflammatory diseases

Muscular Dystrophy Association awards $14.1M in new grants

FDA grants priority review designation of BENLYSTA for systemic lupus erythematosus treatment

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Metagenics announces acquisition of Catalina Lifesciences

PharmaVentures announces global expansion of PharmaDeals Agreements

Innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

Celera Corporation releases review article on KIF6 gene variant for CHD

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

EHSI signs option with Regenevita for 'Neo Natal Progenitor Cell Expansion Technology'

Maternal stress contribute to an elevated risk for depression in offspring: Research

MD Anderson Cancer Center receives $20 million to advance research on targeted therapies

Scientists reveal lab approach method to treat neuroblastoma in children

Siemens Healthcare to distribute Calypso GPS System in Europe

FDA accepts to review Bristol-Myers Squibb's ipilimumab for melanoma

Behavioral Innovations includes In-home Autism Treatment programs in ABA services at San Antonio

Rush University Medical Center tests new drug therapy for West Nile fever

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News